Novo Nordisk announced drastic cuts to the U.S. list prices of several insulin products, reducing costs by up to 75% starting January 1, 2024, in an effort to improve accessibility for patients amidst mounting financial pressures. This decision comes as the company faces a potential full-year sales drop of 5% to 13%, fueled by a notable 11% decrease in U.S. sales during Q1 2026. In parallel, Novo Nordisk is investing in expanding its manufacturing capacity and diversifying its product pipeline, aiming to stabilize its market position while leveraging growth in its GLP-1 weight loss therapies.
“Novo Nordisk · buys · 100 acres · for North Carolina expansion”
“Novo Nordisk · announced · lowering the U.S. list prices of several insulin products · up to 75% effective January 1st, 2024”
“Novo Nordisk · will lower the cost of insulin products · 75% · next year”
“Novo Nordisk · will reduce list price for Novolin and Levemir · 65% · in January 2024”
“Novo Nordisk Inc. · has address · 800 Scudders Mill Road, Plainsboro, NJ 08536, USA”
“Novo Nordisk A/S · has address · Novo Allé, 2880 Bagsvaerd, Denmark”
“Novo Nordisk · is a leading global healthcare company, founded in · 1923 · true”
“Novo Nordisk · employs about · 54,400 people · true”
“Novo Nordisk · markets its products in around · 170 countries · true”
“Novo Nordisk · is lowering the U.S. list prices of several insulin products · pre-filled insulin pens and vials · up to 75%”
“Novo Nordisk · is reducing the list price of · unbranded biologics · to match the lowered price of each respective branded insulin”
“Novo Nordisk · will implement price changes · on January 1, 2024”
.jpg&width=160)